In terms of revenue, the global non-alcoholic steatohepatitis biomarkers market is growing at a CAGR of 23.45% over the forecast period (2021 – 2029).
COVID-19 Pandemic is Expected to Have a Positive Impact
The COVID-19 pandemic has impacted the lives of countless individuals across the globe, and has also put undue pressure on the healthcare and pharmaceutical sector. The evolution of the coronavirus, especially with the recently discovered strain from South Africa, has forced government bodies to implement social distancing norms, and has raised awareness regarding other health conditions such as non-alcoholic steatohepatitis, especially in North America and the Asia Pacific. Individuals are increasingly carrying out diagnostic procedures to check their health conditions, and also trace the presence of various comorbidities. Government bodies have asked people with comorbidities to pay close attention to COVID-19 virus, and treatment is also being sought by various individuals. Hence, the pandemic is expected to have a positive impact on the revenue in the global non-alcoholic steatohepatitis biomarkers market in the coming years.
Request for a Sample Copy: https://www.absolutemarketsinsights.com/request_sample.php?id=967
Hospitals and Clinics Accounted for the Highest Market Share in 2020
Absolute Markets Insights report that hospitals and clinics accounted for the major chunk of the revenue in the global non-alcoholic steatohepatitis biomarkers market in 2020, predominantly due to the easier accessibility of individuals in hospitals and clinics for the diagnosis of this disease. Public healthcare facilities are also incorporating the use of biomarkers for determining the presence of the fatty liver diseases in individuals. Major emphasis is also being provided in hospitals and clinics regarding the presence of non-alcoholic steatohepatitis in children, especially due to the growth in consumption of junk food and oily food amongst kids in urban areas.
Enquiry Before Buying: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=967
Asia Pacific Region to Show the Highest Growth Rate During the Forecast Years (2021-2029)
Based on Absolute Markets Insights estimates, the Asia Pacific region is expected to showcase the highest growth rate during the forecast years in the global non-alcoholic steatohepatitis biomarkers market. The rise in awareness regarding liver conditions such as non-alcoholic steatohepatitis, coupled with the growth in fatty liver issues amongst both children and adults in the Asia Pacific region is a major reason for the higher growth forecast. Studies show that around 9% to 32% of the general population in India is affected by fatty liver disease, and the disease has a higher prevalence amongst individuals with obesity or diabetes. Furthermore, government bodies in the Asia Pacific region are paying attention to the growth in liver diseases. In India, for instance, the Union Health Ministry has raised proposals to integrate non-alcoholic fatty liver disease in the National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS) to cater to the rise in cases of non-communicable diseases in the country. Furthermore, the market participants are setting up local operation centres in the Asia Pacific region to address the growth in demand for the diagnosis and treatment of non-alcoholic steatohepatitis disease. These factors are expected to help in the growth of the Asia Pacific non-alcoholic steatohepatitis biomarkers market.
Some of key players operating in the global non-alcoholic steatohepatitis biomarkers market are Allergan, AstraZeneca, Bristol Myers Squibb Company, Echosens SA , Genfit SA, Gilead Sciences Inc, Madrigal Pharmaceuticals, Medpace, Merck & Co, Novartis AG, Novo Nordisk, Pfizer Inc, ProSciento+ NORDIC BIOSCIENCE, Siemens Healthcare GmbH, Viking Therapeutics, ZydusCadila, amongst others.
Request for Customization: https://www.absolutemarketsinsights.com/request_for_customization.php?id=967
Global Non-Alcoholic Steatohepatitis Biomarkers Market
By Biomarker Type
- Inflammation Biomarkers
- Apoptosis Biomarkers
- Fat Accumulation Biomarkers
- Serum Biomarkers
- Others (Fat metabolism, antioxidants, etc.)
By Diagnosis
- Liver Biopsy
- Histological assessment of liver tissue
By Patient Type
- Adult
- Pediatric
By End-User
- Hospitals and Clinics
- Research& Academic Institutes
- Diagnostics
- Pharma Companies
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Click Here For More Information: https://www.absolutemarketsinsights.com/reports/Global-Non-Alcoholic-Steatohepatitis-Biomarkers-Market-2021---2029-967
Contact Us:
Company: Absolute Markets Insights
Email Id: [email protected]
Phone: IN +91-740-024-2424, US +1-510-420-1213
Contact Name: Shreyas Tanna
Website: www.absolutemarketsinsights.com